Golbi 150 Tablet contains Ursodeoxycholic Acid 150 mg, a hydrophilic bile acid used primarily for the treatment of certain liver and gallbladder disorders. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile, thereby decreasing cholesterol saturation and promoting the dissolution of cholesterol gallstones. It also exerts cytoprotective effects on hepatocytes by stabilizing cell membranes and improving bile flow, which aids in the management of cholestatic liver diseases such as primary biliary cholangitis. Golbi 150 is indicated for patients with non-calcified cholesterol gallstones who are not candidates for surgical intervention, as well as for the treatment of primary biliary cirrhosis to delay disease progression. The medication is typically administered orally, with dosage and duration tailored according to the clinical condition and patient response. Common side effects may include diarrhea, abdominal discomfort, and mild nausea, which are generally transient. Caution is advised in patients with biliary obstruction or acute inflammation of the gallbladder. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential adverse effects. Golbi 150 Tablet should be used under medical supervision to ensure optimal therapeutic outcomes.